AstraZeneca PLC (AZN)

27.91
NYSE : Health Care
Prev Close 27.91
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.55 / 35.04
Avg Volume 7.89M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 72.03B
EPS 1.10
P/E Ratio 12.78
Div & Yield 0.90 (3.20%)

Latest News

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Shell, AstraZeneca Could Surprise in 2017, Credit Suisse Says

Shell, AstraZeneca Could Surprise in 2017, Credit Suisse Says

AstraZeneca and Royal Dutch Shell will surprise investors.

Here's Why General Motors Is One of Wednesday's Most Active Stocks

Here's Why General Motors Is One of Wednesday's Most Active Stocks

GM, Bank of America and AstraZeneca are among today's active movers. Here's how to trade them.

Hey, What About the Transports?

They were red today and no one seems to care.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.

Alexion Announces Phase Two Trial Failure, Falls Slightly After Hours

Alexion Announces Phase Two Trial Failure, Falls Slightly After Hours

The biotech company has been taking a beating lately.

Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights

Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights

Akebia's vadadustat is designed to stimulate the production of red blood cells (and the oxygen-carrying molecule hemoglobin) by mimicking the body's reaction to high altitudes.

Innate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman

Innate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman

Meanwhile, Astrazeneca's shares fall as its head of oncology leaves for the smaller biotech company.

Ionis Earns $28 Million From AstraZeneca For A New Drug To Treat Cancer

Ionis Earns $28 Million From AstraZeneca For A New Drug To Treat Cancer

- AstraZeneca Exercises Option to License IONIS-KRAS-2.5 Rx (AZD4785)

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks on Track for Fresh Records as Health Care Sector Climbs

Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results

Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks Extend Rally as Health Care Sector Makes Comeback

Stocks move higher on Friday, trading at records, as the health care sector makes a comeback after a bruising week.

Stocks Set to Extend Their Record Run Following Wall Street's Surge

Stocks Set to Extend Their Record Run Following Wall Street's Surge

Stock futures move slightly higher on Friday, setting Wall Street to open at record highs after Thursday's session continued the markets' winning streak.

Analysts' Actions -- Autodesk, Aflac, AstraZeneca, Duluth and More

Analysts' Actions -- Autodesk, Aflac, AstraZeneca, Duluth and More

Here are Friday's top research calls, including upgrades for Autodesk and AstraZeneca, and downgrades for Aflac and Duluth.

AstraZeneca Announces Subgroup Analysis From FALCON Trial Comparing FASLODEX® (fulvestrant) To ARIMIDEX® (anastrozole)

AstraZeneca Announces Subgroup Analysis From FALCON Trial Comparing FASLODEX® (fulvestrant) To ARIMIDEX® (anastrozole)

AstraZeneca today announced results from a pre-specified subgroup analysis of the positive Phase III FALCON trial suggesting that treatment effects in terms of progression-free survival (PFS) were largely consistent across...

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.

TAGRISSO® (osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

TAGRISSO® (osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

AstraZeneca today presented data from the AURA3 trial that is supportive of TAGRISSO ® (osimertinib) potentially becoming the new standard of care for second-line treatment of patients with epidermal growth factor...

Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-to-Treat Chronic Lymphocytic Leukemia

Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-to-Treat Chronic Lymphocytic Leukemia

AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat...

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Is This the Pullback I Ordered?

This could be cause for celebration.

AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function In Pediatric Asthma Patients

AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function In Pediatric Asthma Patients

Results from the international, multicenter Child Hood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.